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Abstract
A genome scan meta-analysis (GSMA) was carried out on 32 independent genome-wide linkage
scan analyses that included 3255 pedigrees with 7413 genotyped cases affected with schizophrenia
(SCZ) or related disorders. The primary GSMA divided the autosomes into 120 bins, rank-ordered
the bins within each study according to the most positive linkage result in each bin, summed these
ranks (weighted for study size) for each bin across studies and determined the empirical probability
of a given summed rank (PSR) by simulation. Suggestive evidence for linkage was observed in two
single bins, on chromosomes 5q (142-168 Mb) and 2q (103-134 Mb). Genome-wide evidence for
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linkage was detected on chromosome 2q (119-152 Mb) when bin boundaries were shifted to the
middle of the previous bins. The primary analysis met empirical criteria for ‘aggregate’ genome-
wide significance, indicating that some or all of 10 bins are likely to contain loci linked to SCZ,
including regions of chromosomes 1, 2q, 3q, 4q, 5q, 8p and 10q. In a secondary analysis of 22 studies
of European-ancestry samples, suggestive evidence for linkage was observed on chromosome 8p
(16-33 Mb). Although the newer genome-wide association methodology has greater power to detect
weak associations to single common DNA sequence variants, linkage analysis can detect diverse
genetic effects that segregate in families, including multiple rare variants within one locus or several
weakly associated loci in the same region. Therefore, the regions supported by this meta-analysis
deserve close attention in future studies.
Keywords
genome; human; humans; schizophrenia/genetics; genetic predisposition to disease; linkage
(genetics); meta-analysis
Introduction
We report here on a new genome scan meta-analysis (GSMA)1-3 of genome-wide linkage scans
(GWLS) of schizophrenia (SCZ). We previously published a GSMA of 20 scans that included
1208 pedigrees with 2945 genotyped affected individuals.4 Here we analyze 32 scans that
included 3255 pedigrees with 7413 affected individuals.
Genome-wide association (GWA) study methods have proven more successful than GWLS
for common diseases: they detect smaller effects of common single nucleotide polymorphisms
(SNPs)5 as well as some copy number variants (CNVs),6 and have identified many common
disease associations.7 But an adequately powered GWLS can detect a signal from many kinds
of susceptibility variants (common SNPs, multiple rare SNPs, tandem repeats and heritable
structural variations) in one or more8 loci in a region. Meta-analysis can achieve much larger
sample sizes than single studies. Consensus linkage regions may deserve further study using
methods such as high-throughput resequencing.
Family and twin data9 suggest that most of the genetic risk to SCZ is conferred by multiple
interacting loci, each causing a small increase in risk. As SCZ has similar symptoms and
roughly similar prevalence throughout the world,10 a reasonable hypothesis is that at least some
loci have effects in many populations. SCZ linkage findings do not replicate consistently, and
although there may be some true positives in small samples from unique populations, in
general, power is probably limited by inadequate sample size and differences in ascertainment,
marker sets, ancestry and statistical methods. There must also be some measurement error due
to limitations in diagnostic methods. Current diagnostic criteria produce the largest known
estimates of heritability (twins) and of increased risk to first-degree relatives,11,12 and there is
good diagnostic reliability within and across research groups.13 But diagnostic judgments are
based on data from interview and medical records that vary in completeness and quality.
Fortunately diagnostic differences are usually among psychotic disorders that coaggregate in
families with similar risks.14 It is not known whether a further subdivision of cases would
increase power.
We present a GSMA of all 32 scan analyses, and a secondary analysis of 22 European-ancestry
analyses. The new samples (some of them large) are from European, non-European and isolate
populations, but are too diverse to consider a subset other than Europeans. We comment briefly
below on an analysis of heterogeneity between Asian and European samples. Statistical
significance has been evaluated with permutation tests and simulations. In the primary analysis,
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2 bins met empirical genome-wide criteria for suggestive linkage; and a set of 10 bins (in eight
chromosomal regions) met an empirical aggregate criterion for genome-wide significant
linkage, indicating that loci linked to SCZ are present in some or all of these bins. Five of these
bins were consistent with our previous report.4 When bin boundaries were shifted to the middle
of the previous bins, one genome-wide significant result was observed on chromosome 2q,
consistent with our previous report.4
Materials and methods
Study selection
We identified GWLS of SCZ (in addition to those studied previously4) through PubMed
literature searches, conference abstracts and personal contacts with investigators, selecting the
largest analysis for each study. Study characteristics are summarized in Table 1. Investigators
of each of these studies agreed to contribute data to this analysis. All scans ascertained probands
with SCZ by one of three closely related sets of diagnostic criteria. Most scans included
relatives with SCZ and those with one or all subtypes of schizoaffective disorder (SA). A few
scans included only SCZ cases, or included broader diagnoses in alternative models. Scans
were included if informative families ascertained through a SCZ case had at least 30 genotyped
SCZ and SA cases. We included only primary genome-wide analyses with few gaps in marker
coverage, and did not consider subsequent ‘fine mapping’ with additional markers or pedigrees
in selected regions. We excluded a small Utah study48 whose RFLP markers were difficult to
place on the current map; a study of a large Costa Rican pedigree49 with too few affected cases;
a small study from an Italian isolate population50 that combined SCZ and bipolar cases; and a
study of isolated villages in Daghestan51 that used a very broad phenotype definition. We
lacked detailed results for the Icelandic study of Stefansson et al.52 We included two earlier
studies of Icelandic families for which we had complete results,15,20 and discuss below a
secondary analysis substituting results from Stefansson et al. inferred from published graphs.
A companion paper38 reports on a combined analysis of studies 24-31 (Table 1). Older data
for all or parts of six of those data sets were included as separate scans in our previous GSMA,
so all eight are treated separately here using the newer data.38 To eliminate sample overlap,
investigators provided us with data for NUH (study 28) that excluded families that were also
in the US/International study (study 9); and data for sample 15 (US/Sweden) without families
in sample 26 (Cardiff). The investigators determined from genotypes that there were no
overlapping families in samples 10 and 22.
There were 14 studies of European-ancestry pedigrees (including partial isolates such as
Finland and Ashkenazim); 8 of both European and non-European families; and 10 non-
European samples, including 3 Asian (Japanese, Han Chinese and Indonesian), 2 Latino, 1
Arab, 2 Pacific Island isolates (Palau and Kosrae) and 2 entirely (study 20) or predominantly
(study 6) African-American samples. Study 6 (Texas) included a few European-ancestry
families for which we lacked separate data. The ALL analysis included all 32 samples; the
EUR (European-ancestry) analysis included 22 samples or subsamples (Table 1). Data for
chromosome X markers were available for 23 studies, so this chromosome was considered in
a secondary analysis.
Linkage scores were obtained from investigators or internet postings. Data for each study were
rank ordered based on the designated ‘primary’ analysis, and if this included more than one
test or model, we took the most positive linkage score across tests for each chromosomal bin.
From our previous GSMA,4 data were carried over unchanged for studies 1-10 in Table 1; the
Utah study48 was omitted as discussed above; and nine studies were updated with new
genotyping results, some with larger samples. Studies 13 and 24-31 used SNP markers from
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the Illumina version 4 panel; all other studies used microsatellite markers at approximately
8-10 cM density.
Marker mapping
Marker locations were determined from the Rutgers combined linkage map (Build 36),53 or
interpolated based on physical position, other maps or flanking markers. Chromosomes were
divided into bins of approximately equal genetic widths—120 30-cM bins (our primary
analysis), or (for secondary analyses) 179 20-cM bins and 88 40-cM bins. Six additional 30-
cM bins were defined on the X chromosome (female map length). If a study had no marker in
a bin (for example, the narrower 20 cM bins), we used the mean linkage score for the two
flanking markers, or the single closest marker for an empty telomeric bin. Bin boundaries in
cM and Mb are listed in online Supplementary Table 1.
Statistical analysis
GSMA is a nonparametric method to combine data generated with different maps and statistical
tests.1-3 A GSMA divides the genome into approximately equal-width bins (Nbins), labeled
ch.K, where ch = chromosome and K = bin number (that is, 1.4 is the fourth bin of chromosome
1). For each study, bins are ranked by their highest LOD, NPL or Z score or minimum P-value.
Ranks for each sample was weighted by the square root of the number of genotyped affected
cases, and then, for comparison, analyzed without weights (results of unweighted analyses are
provided in the online Supplementary Materials). Note that ‘120’ was the best rank, and higher
summed ranks indicate stronger evidence for linkage (whereas in our previous report,4 ‘1’ was
the best rank in a study and we reported averaged rather than summed ranks).
We used GSMA software2 to evaluate nominal (binwise) significance by randomly permuting
the ranks for bins within each study and then resumming the ranks across studies to determine
the empirical summed rank probability (PSR)—the nominal probability that a bin would
achieve or exceed the observed summed rank under the null hypothesis of no linkage in the
bin. We also determined the empirical ordered rank P-value (POR—the probability that the
kth highest summed rank achieves or exceeds an observed summed rank under the null).
Thresholds for genome-wide significant and suggestive evidence for linkage54 were
determined empirically (see below). For the primary analysis, these thresholds were PSR <
0.00037 and PSR < 0.0077 respectively.
Strong linkage signals can cover a wide genetic region in complex disorders, and often produce
high summed ranks in adjacent bins,1 but GSMA can miss a weak linkage signal near the
boundary of two bins. Therefore, regions showing suggestive evidence for linkage were
reanalyzed using 20 and 40 cM bin widths, and using 30 cM bins starting at the midpoint of
the bins used in the primary analysis (Supplementary Figure 1).
We tested for heterogeneity in study ranks between three outbred Asian studies (Taiwan, Japan,
Indonesia) and the 22 EUR studies, using the nonparametric Wilcoxon rank sum test. We did
not test for heterogeneity arising from an arbitrary set of studies;55 these tests detect bins where
study ranks have a wider spread than expected by chance, but they have low power and do not
identify the study subgroups contributing to the heterogeneity.56 We also carried out sensitivity
analyses, dropping one study at a time and analyzing the remaining studies with GSMA
(weighted and unweighted analyses, 30 cM bins).
Simulation study of power and significance thresholds
We performed a simulation study to determine: (1) power; (2) permutation-based estimates of
type I error and (3) aggregate criteria for genome-wide significance. Details are provided in
Supplementary Online Materials and in a previous report.1 Briefly, genome-wide data were
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simulated for affected sibling pairs under the assumption of no linkage or assuming a range of
genetic models (1-10 linked bins with locus-specific sibling relative risks (λS) of 1.15 or 1.3,
at the edge or near the middle of chromosomes), and 1000 replicates of the 32-sample data set
(or of alternative subsets of the data) were created by replacing each sample with a number of
ASPs with roughly comparable linkage information.
For estimates of type 1 error, we determined empirical bin-wise thresholds for genome-wide
suggestive linkage (the nominal P-value observed on average once per GSMA replicate) or
genome-wide significant linkage (the nominal P-value observed on average in 5% of GSMA
replicates).
We also determined criteria for aggregate genome-wide significant linkage, that is, that the
total number of bins achieving a specified nominal P-value threshold was greater than that
observed in 5% of genome-wide replicates with no linkage present. This criterion was
determined for ALL and EUR studies by establishing a P-value threshold, P0, for which exactly
5% of unlinked replicates had N or more bins with PSR < P0. P0 was initially set at 0.05, and
the number of unlinked replicates with ≥N bins achieving PSR < P0 was tabulated ( for N = 1,
2, 3,...). P0 was then reduced incrementally until exactly 5% of simulations had at least N bins
with PSR < P0, for some value N. For example, for the primary weighted analysis of 32 studies,
the 5% genome-wide threshold by this procedure was 10 bins with P < 0.046; for EUR studies,
it was 10 bins with P < 0.048.
For power calculations, we determined how often, on average, the linked bins exceeded the
PSR threshold for ALL and for EUR studies, and, to investigate heterogeneity, for ALL studies
assuming that linkage arose only in EUR studies.
Results
Evidence for linkage (ALL and EUR studies)
Figure 1 illustrates P-values for all bins in the ALL and EUR analyses, and the figure legend
states the empirical P-value thresholds for each study. For ALL studies (3255 pedigrees, 7413
genotyped cases), Table 2 lists the 10 bins (in eight nonadjacent chromosomal regions) that
achieved PSR < 0.05 in the primary analysis (weighted, 30 cM bins). These 10 bins met the
empirical aggregate criterion for genome-wide significant linkage (10 bins with nominal
PSR < 0.046). Suggestive evidence for linkage was observed for single bins on chromosome
5q (bin 5.6, PSR = 0.0046) and chromosome 2q (bin 2.5, PSR = 0.0075). Figure 1 illustrates
the results for all bins (ALL and EUR analyses), and Figure 2 illustrates the relative ranks of
bins in each study. (Results for all analyses are available in Online Supplementary Tables;
ranks for each study are available online at www.kcl.ac.uk/mmg/ngdata.html.)
Table 3 summarizes results for 22 EUR samples or subsamples (1813 pedigrees, 4094
genotyped cases). Suggestive evidence for linkage was observed on chromosome 8p (PSR =
0.00057, close to the genome-wide threshold for 22 EUR studies of 0.00044), with a further
five bins in four different regions achieving nominal significance.
On chromosome X, there were no nominally significant bins for ALL studies; there was one
such bin (X.5, 130-162 cM, 119-141 Mb, PSR = 0.0247) for EUR studies.
When estimated ranks (interpolated from published graphs) for the Icelandic study of
Stefansson et al.52 were substituted for the results of Gurling et al.20 and Moises et al.,15 results
were similar to those shown in Table 1 except that bin 3.4 failed to achieve nominal
significance. For EUR studies, results again were similar except that bins 8.2 and 2.8 both
achieved suggestive significance.
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Effect of bin width
Online Supplementary Figures 2-4 illustrate results of analyses using four alternative bin
widths (20, 30 and 40 cM, and 30 cM bins shifted by 50% for chromosomes with suggestive
evidence for linkage (chromosomes 2 and 5 for ALL, chromosome 8 for EUR). On
chromosome 2, genome-wide significance was obtained for the shifted 30 cM bin (PSR =
0.00035, 132.2-161.6 cM, 118.7-152 Mb), and suggestive linkage evidence was seen in the
adjacent bin (102.8-132.2 cM, 84.9-118.7 Mb). For the region of chromosome 5q that produced
suggestive evidence for linkage in the primary analysis, the signal was similar regardless of
bin width. On chromosome 8, using 20 cM bins extended the signal by approximately 5 cM
in both directions; if linkage is present, this pattern could indicate a broader signal (multiple
loci) or the effects of a single strong signal on adjacent bins.
Heterogeneity and sensitivity analyses
In tests of differences between 22 EUR vs 3 Asian studies, none of the 120 bins exceeded
nominal P < 0.01, and only 4 bins achieved nominal P < 0.05, thus, no significant difference
was observed. The most significant evidence for heterogeneity between the Asian and
European studies was in bin 1.5, but this did not reach the suggestive threshold (online
Supplementary Figure 5). Results of sensitivity analyses, omitting each study in turn, are shown
in online Supplementary Figures 6 and 7. The largest changes: bin 8.2 (8p) achieves the
suggestive linkage threshold without the Taiwan data set; bin 2.8 (2q) becomes substantially
more significant (but not achieving genome-wide significance) without the Japan data set; bin
5.6 (5q) becomes substantially more significant (but not genome-wide significant) without the
Suarez et al. data set (study 21); and bin 6.3 (6pq) would join the list of nominally significant
bins without either the Taiwan or Japan data set.
Type I error
Type I error was calculated for the unlinked GSMA simulations (120 000 30-cM bins) by
determining the number of observed bins in which the GSMA program computed PSR values
(based on permutation alone) that were less than the theoretical threshold for nominal
significance (0.05); for genome-wide suggestive linkage, or a value expected once per GSMA
(1/120 = 0.00833) or genome-wide significant linkage (0.05/120 = 0.00042). The GSMA
program’s permutation procedure produced type I errors that were slightly liberal for ALL
(0.053, 0.0096 and 0.00051) and less liberal for EUR studies (0.051, 0.0091 and 0.00042). The
source of the discrepancy is not clear, but we have used the permutation-based suggestive and
significant values here for single bins (0.0077 and 0.00037 for ALL, and 0.0078 and 0.00044
for EUR studies) and an empirical threshold for aggregate genome-wide significance as
described above.
Power
Table 4 summarizes the results of power calculations from simulation studies. Power is lower
for edge bins for multipoint analyses, so we computed a weighted average of power assuming
20% edge and 80% mid-chromosome bins (see Table 4 legend). Power was excellent to detect
significant linkage at multiple loci with observed population-wide λS = 1.3 (30% increased
risk in sibs) across ALL studies or in EUR studies alone. For λS = 1.15, there was excellent
power to detect significant linkage in multiple bins (for ALL studies), or to detect suggestive
evidence for linkage in multiple bins (if limited to EUR studies); there was reduced power in
the presence of substantial heterogeneity. Genetic effects limited to a defined subset (EUR)
were more readily detected in a separate analysis.
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Discussion
Meta-analysis of 32 GWLS, encompassing 7413 individuals affected with SCZ or related
disorders in 3255 pedigrees, produced evidence for significant linkage in the genome based on
empirical aggregate criteria: 10 30-cM bins that achieved bin-wise PSR < 0.046. Genome-wide
evidence for linkage was detected on chromosome 2q (118.7-152 Mb) in a secondary analysis
that shifted bin location by 50%, consistent with our previous finding of significant linkage in
the same region in our previous GSMA of 20 studies.4 Suggestive evidence for linkage was
detected in ALL studies in two single bins, on chromosomes 5q and 2q. Separate analysis of
European-ancestry samples produced linkage evidence falling just short of the genome-wide
significance in bin 8.2 (15.7-32.7 Mb).
It is widely assumed that many loci contribute to SCZ susceptibility. Table 4 shows that for
the GSMA method, power to detect at least one true linkage goes up with the number of linked
loci, but the power to detect any specific locus decreases, because in a rank-ordered test there
is a finite number of high ranks in each study. But if there were many loci with locus-specific
λS values of 1.3 or even 1.15 (averaged across all study populations and accounting for the
effects of various sources of measurement error), we would expect to detect genome-wide
significant linkage in several individual bins, and suggestive evidence for linkage in many
more than two bins. It would be reasonable to conclude that there are probably no loci with
such strong effects worldwide or across all European populations, although they might exist
within particular populations for which samples of this size are not available or within subsets
of families, which we cannot yet identify in advance.
The power of linkage analysis for a locus is predicted by its contribution to the relative risk
(RR) to siblings of probands (λS),57 whereas the power of association analysis is predicted by
allelic or genotypic RRs, that is, the increased risk to individual carriers.5 GWA studies have
produced robust association findings for many complex genetic disorders58-60 typically with
RRs of 1.1-1.5. A variant found on 10% of chromosomes conferring a ‘large’ RR of 1.5 per
allele in a multiplicative model (2.25 for homozygous carriers) would produce a population-
wide sibling RR of only 1.02 (undetectable by linkage). But GWA chips are unlikely to tag all
pathogenic variants. For example, in NOD2 there are three rare variants, each with a frequency
of less than 5%, that confer moderate risks of Crohn’s disease. Their individual effects generate
only weak signals when assayed by the Affymetrix 500K chip because they are poorly tagged;
but combined, they confer a sibling RR of 1.16, which is detectable in a very large linkage
sample.58,61 This illustrates a strength of linkage analysis: allelic heterogeneity is difficult to
detect in association studies, as the genetic effect is split across variants, but linkage can detect
the pooled effect of all variants (not only SNPs) within one or more susceptibility genes or
elements in a region.
Readers may be interested to know the location of SCZ candidate genes or regions in relation
to bins that produced evidence for linkage here. On chromosome 1q, NOS1AP (160 Mb;
previously known as CAPON),62,63 RGS4 (161.3 Mb)64,65 and UHMK1 (160.7 Mb)66 are
near the telomeric edge of bin 1.6 (114.6-162.1 Mb), and the rare (usually de novo) SCZ-
associated CNV is located in a different part of the same bin (145-146 Mb).67,68 On
chromosome 8p, PPP3CC (22.35 Mb)69 and NRG1 (31.6-32.7 Mb)52,70 are both within bin
8.2 (15.7-32.7 Mb). On chromosome 2q, ZNF804A, which contains a SNP that produced
genome-wide significant evidence for association in a combined SCZ-bipolar disorder sample,
71 is in bin 2.7 at 185 Mb. This bin was not nominally significant in the primary analysis, but
185 Mb is within nominally significant bins in two secondary analyses (one that shifted bin
boundaries by 50% and one that considered 40 cM bin widths). DTNBP1, DAOA, TRAR4/
STX7, CHRNA7, COMT/ARVCF, DISC1, AKT1, HTR2A and DRD2 are not in bins listed
in Tables 2 or 3. Many of the research groups whose samples are included here are actively
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investigating association of SCZ to sequence variants in genes identified in linkage regions or
by the more recent genome-wide association methodology.
In conclusion, this updated GSMA of 32 SCZ studies showed significant evidence for linkage
on chromosome 2q in a secondary analysis, suggestive evidence for linkage on chromosomes
5q and 2q in the primary analysis, and suggestive evidence for linkage on 8p in European
samples. Genome-wide significant aggregate evidence for linkage (that is, more modestly
significant results than expected by chance) was observed based on results for 10 bins in 8
nonadjacent chromosomal regions. As results from genome-wide association studies emerge,
it may be important to keep in mind that there may be SCZ susceptibility loci in some of these
consensus linkage regions that cannot be detected by common tag SNPs. It is likely that diverse
methods will be required to identify specific DNA sequence variants and to confirm and define
their role in the etiology of SCZ.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Genomewide results for primary analysis (weighted, 30 cM bins) for ALL studies (red) and
EUR studies (blue). The two upper dashed lines represent empirical thresholds for genomewide
significant (theoretical PSR = 0.00037) and suggestive (theoretical PSR= 0.0077) evidence for
linkage for a single bin for ALL studies; and the lower dashed line represents the threshold for
aggregate significance for ALL studies (theoretical PSR = 0.046 in 10 or more bins). The
thresholds for EUR studies were slightly less stringent (PSR values of 0.00044, 0.0078 and
0.0475 (in 10 or more bins) respectively), but the Figure shows all EUR bins within the region
for their correct threshold of significance.
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Figure 2.
Ranks by study and summed ranks. Shown for each study is the within-study rank of each bin.
‘1’ against a red background indicates bins with ranks of 116-120 (the bin containing the most
significant linkage score in a study is ranked 120); 2 indicates ranks 111-115; 3—ranks
101-110; 4—ranks 81-100; 5—ranks 61-80; 6—ranks 41-60; 7—ranks 21-40; and 8—ranks
1-20 (cells with 7 and 8 have a white background). Shown at the top of each part of the figure
are the bin number, the weighted summed rank for each bin across studies (i.e., weighted for
each sample by the square root of the N of genotyped affected individuals), and the rank-
ordered position of that bin in the ALL analysis (i.e., 1 is the best position, see details in Table
2). Purple background indicates bins with empirical suggestive evidence for linkage in the ALL
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analysis; 10 bins shaded in purple, yellow or blue met the threshold for aggregate genome-
wide evidence for linkage (10 bins with nominal P < 0.046); and bin 8.2 (shaded blue) also
met empirical suggestive evidence for linkage in the EUR analysis. Shown at the bottom is the
distal boundary of each bin in Rutgers cM and in Mb (build 36). Note that tied ranks can result
in uneven numbers of bins in a grouping, particularly for lower ranks when there are many
zero or negative scores. See Table 1 for the references associated with each study.
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ra
bl
e 
to
 th
e 
32
 st
ud
ie
s i
n 
th
e 
sc
hi
zo
ph
re
ni
a 
G
SM
A
 (1
20
 3
0-
cM
 b
in
s)
. λ
S 
= 
re
la
tiv
e 
ris
k 
to
 si
bl
in
gs
 o
f c
as
e 
pr
ob
an
ds
vs
 p
op
ul
at
io
n 
ris
k.
 F
or
 1
 li
nk
ed
 b
in
 p
er
 si
m
ul
at
ed
 g
en
om
e,
 p
ow
er
 is
 a
 w
ei
gh
te
d 
av
er
ag
e 
as
su
m
in
g 
th
at
 2
0%
 o
f b
in
s l
ie
 a
t a
 c
hr
om
os
om
e 
en
d 
(‘
ed
ge
,’ 
se
e 
te
xt
), 
an
d 
80
%
 o
f a
re
 m
id
-c
hr
om
os
om
al
 (‘
m
id
’)
. S
im
ul
at
io
ns
 w
ith
 5
 li
nk
ed
 lo
ci
 in
cl
ud
ed
 1
 e
dg
e 
an
d 
4 
m
id
 b
in
s;
 th
os
e
w
ith
 1
0 
lin
ke
d 
in
cl
ud
ed
 2
 e
dg
e 
an
d 
8 
m
id
 b
in
s.
a H
et
er
og
en
ei
ty
 a
na
ly
se
s m
od
el
le
d 
ca
se
s w
he
re
 a
ll 
sa
m
pl
es
 w
er
e 
in
cl
ud
ed
, b
ut
 E
ur
op
ea
n 
sa
m
pl
es
 w
er
e 
lin
ke
d 
as
 sh
ow
n 
w
hi
le
 n
on
-E
ur
op
ea
n 
st
ud
ie
s w
er
e 
un
lin
ke
d.
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